Literature DB >> 2775050

The role of bronchoalveolar lavage in the assessment of diffuse lung diseases.

P G Gibson1, B W Robinson, G McLennan, D H Bryant, S N Breit.   

Abstract

Bronchoalveolar lavage is a safe and simple technique for sampling the inflammatory cells of the lung. However, while its use in the evaluation of pulmonary pathogenic mechanisms is both well accepted and described, its clinical utility is more controversial. Marked variation in results may occur through variation in the lavage procedure. Standardisation of the lavage technique and laboratory processing of the specimen are essential for reliable results. This review examines the current clinical role of bronchoalveolar lavage in the assessment of patients with diffuse lung diseases, and immunocompromised patients with pulmonary infiltrates. In this latter category, for patients with Acquired Immunodeficiency Syndrome, lavage is of equal efficacy to lung biopsy and can establish the cause of pulmonary infiltrates in over 90% of cases. Bronchoalveolar lavage can detect abnormalities in patients with diffuse lung diseases prior to the development of irreversible fibrosis. Lavage features have been described for sarcoidosis, cryptogenic fibrosing alveolitis, extrinsic allergic alveolitis, connective tissue diseases, and asbestosis. In cryptogenic fibrosing alveolitis lavage data may be used to indicate a subsequent deterioration in the patient's condition, or predict a favourable response to therapy.

Entities:  

Mesh:

Year:  1989        PMID: 2775050     DOI: 10.1111/j.1445-5994.1989.tb00263.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  2 in total

1.  Quantitative pulmonary gallium scanning in interstitial lung disease.

Authors:  S C Ramsay; M G Yeates; W M Burke; D H Bryant; G W Morgan; S N Breit
Journal:  Eur J Nucl Med       Date:  1992

Review 2.  How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies.

Authors:  Bruce W S Robinson; Alec J Redwood; Jenette Creaney
Journal:  Front Pharmacol       Date:  2022-03-31       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.